GlobalData on MSN
Silver Creek’s stroke hopeful yields mixed results in Phase II trial
If approved, the targeted IGF-1 fusion protein would become the only treatment available for late-window stroke patients ...
11d
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up ...
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...
LOS ANGELES -- A course of transcranial direct current stimulation (tDCS) did not help with post-stroke motor recovery when tested in a larger multicenter randomized trial. Among stroke survivors 1-6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback